This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e61. Learning Objective-Upon completion of this activity, successful learners will be able to demonstrate an increase in, or affirmation of, their clinical knowledge of nonalcoholic fatty liver disease and identify the role of bariatric surgery in nonalcoholic fatty liver disease treatment.
N onalcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in the world, affecting 20% to 30% of the general population in Western countries and costing the US health care system $32 billion annually. 1, 2 NAFLD is the hepatic manifestation of metabolic syndrome and its prevalence has increased with the obesity epidemic, affecting up to 90% of morbidly obese patients. 3, 4 NAFLD is characterized by hepatic steatosis that can progress to nonalcoholic steatohepatitis (NASH), characterized by inflammation and hepatocellular injury. NASH is the second most common indication for liver transplantation in the United States, 5 and affected patients are also at a higher risk for liver-related death owing to progression to fibrosis, cirrhosis, and hepatocellular carcinoma. 6 Currently, there are no approved therapies to treat NAFLD, and most treatments involve controlling underlying factors of the metabolic syndrome. 7 The first-line treatment is weight loss; however, the 10% weight loss required to reduce inflammation and fibrosis in patients with NASH is difficult to maintain. 8, 9 Pharmacotherapy for NAFLD includes insulin sensitizers such as pioglitazone, antioxidants including vitamin E, and glucagon-like peptide-1 analogues, which have limited evidence but are the subject of ongoing trials. 7, [10] [11] [12] Bariatric surgery has proven to be effective for achieving sustained weight loss in patients and can reverse risk factors that contribute to the pathogenesis of NAFLD, including dyslipidemia, insulin resistance, and inflammation, making it a promising treatment option for NAFLD. 13, 14 Initial studies raised concerns that rapid weight loss from bariatric surgery could exacerbate steatohepatitis or acute liver failure in morbidly obese patients, 15 ,16 but more recent surgical techniques such as Roux-en-Y gastric bypass have shown improvements in liver histopathologic scoring after 5 years of follow-up evaluation. 17, 18 Although the majority of studies have reported that fibrosis scores improve after bariatric surgery, a number of studies also have noted development de novo and worsening of fibrosis in a small subset of their patients. [18] [19] [20] [21] Despite the lack of randomized trials, guidelines have indicated that bariatric surgery reduces liver fat and is likely to reduce the progression of NAFLD. 22, 23 However, a nationwide analysis found that despite an association between prior bariatric surgery with decreased mortality in 45,462 morbidly obese patients with NAFLD, the proportion of NAFLD patients receiving bariatric surgery decreased from 2004 to 2012. 24 Given the considerable number of studies with larger sample sizes that have accumulated in recent years, this systematic review and meta-analysis aims to establish the harms and benefits of bariatric surgery on histologically confirmed resolution of NAFLD (steatosis, inflammation, ballooning degeneration, and fibrosis), NAFLD activity score (NAS), and histologic worsening of NAFLD.
Methods

Search Strategy
We searched the following databases covering the period from database inception through May 2018: MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. The search was designed and conducted by a medical librarian with input from study investigators (the complete search strategy is available in Supplementary Table 1) . We also searched the references of published studies and searched grey literature (eg, conference abstracts, presentations, proceedings, unpublished trial data) manually to ensure that relevant articles were not missed. We did not discriminate full texts by language. This systematic review and meta-analysis is reported in accordance with the Preferred Reporting items for Systematic Reviews and Meta-Analyses. 25 The protocol of this study was registered before commencement in the Prospective Register of Systematic Reviews (CRD42018093012).
Eligibility Criteria and Data Abstraction
Articles were eligible for inclusion if the studies examined the effect of bariatric surgery on NAFLD. We included both single-arm studies (effect of bariatric surgery on NAFLD status before and after surgery) or double-arm studies (bariatric surgery vs placebo or medical therapy). However, there were no double-arm studies identified in the current literature. Exclusion criteria were as follows: (1) case-series/reports, expert opinions, basic science, and review articles; (2) nonhuman studies; (3) studies with fewer than 10 eligible patients; and (4) patients with cirrhosis or a history of liver transplants.
At least 2 reviewers independently screened the searched titles, abstracts, and full texts following the inclusion and exclusion criteria. Reviewers were not blinded to authors, institution, or the journal in which the article was published. Discrepancies that occurred at the title and abstract screening stages were resolved by automatic inclusion to ensure that all relevant articles were not missed. Discrepancies at the full-text or data abstraction stage were resolved by consensus between 2 reviewers, and if disagreement persisted, a third reviewer was consulted. Two reviewers independently What You Need to Know Background Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease with substantial burden and no approved treatments. The prevalence of NAFLD has increased substantially with the obesity epidemic.
Findings
Our systematic review and meta-analysis found that weight loss induced by bariatric surgery leads to biopsy-confirmed resolution of NAFLD and improvement of the NAFLD Activity Score in a substantial proportion of patients.
Implications for patient care
If bariatric surgery should be found to be safe and effective for NAFLD through larger randomized trials, consideration should be given to treating obese patients with NAFLD with bariatric surgery.
conducted data abstraction onto a standardized spreadsheet designed a priori. The following data were abstracted from included studies: study characteristics (author, country, year of publication, study design, and funding source), patient demographics (mean age at time of surgery, percentage of female patients, number of patients included, comorbidities, and mean body mass index [BMI] before and after surgery), follow-up time points, type of bariatric surgery, biopsy description (type of histopathologic grading system, biopsy method, reason for follow-up biopsy, number of paired liver biopsy specimens for histologic analysis before and after surgery), and outcomes.
Outcomes Assessed
Articles included in the systematic review and metaanalysis reported at least 1 of our 4 outcomes of interest before and after surgery, which included the following: (1) histologic (biopsy) features of NAFLD such as steatosis, inflammation, ballooning degeneration, and fibrosis; (2) NAS, which is a sum of individual NAFLD biopsy scores; (3) worsening of NAFLD after bariatric surgery; and (4) change in liver volume outcomes after surgery. The primary outcome of our review was biopsyproven complete resolution of NAFLD. Complete resolution of NAFLD was defined as the absence of pathologic biopsy results after bariatric surgery. If a histopathologic grading system had a scale of 0 to 4, then 0 was considered to be complete resolution and 1 to 4 were categorized as disease. Dichotomization of the grading system allowed us to pool and analyze how many patients with NAFLD had complete resolution of NAFLD after bariatric surgery across studies that used different histopathologic grading systems. In several studies, the investigators only reported improvement of NAFLD or did not report complete resolution and improvement of NAFLD separately. We did not include these outcomes because our review strictly focused on the effect of bariatric surgery on complete resolution of NAFLD, without improvement data inflating the results of the overall effect estimate. We also assessed the NAS score, which combines steatosis, lobular inflammation, and hepatocyte ballooning scores to provide a more accurate and complete picture of liver disease than individual histopathologic results. 26, 27 Statistical Analysis
The pooled proportion of patients with complete resolution of steatosis, inflammation, ballooning degeneration, and fibrosis after bariatric surgery was calculated using the Freeman-Tukey double arcsine transformation of proportions. The DerSimonian and Laird random-effects meta-analysis of proportions was used to generate the overall effect size of each outcome.
The same method was applied for the histologic worsening of NAFLD-related outcomes (eg, worsening or new development of fibrosis) after bariatric surgery. We also performed pairwise meta-analyses using a DerSimonian and Laird random-effects model for continuous variables such as NAS before and after surgery. Pooled effect estimates were obtained by calculating the mean difference in outcomes along with their respective 95% CIs to confirm the effect size estimation. In addition, for studies that did not report change in SD, a mean between the baseline SD and the end point SD was calculated. Assessment of heterogeneity was completed using the inconsistency (I 2 ) statistic. We considered I 2 higher than 50% to represent considerable heterogeneity. 28 Publication bias was assessed using a funnel plot. All statistical analyses and meta-analyses were performed on STATA, version 14 (StataCorp, College, TX) and Cochrane Review Manager 5.3 (London, UK), with a level of significance set at a P values less than .05. In addition, we performed subgroup analyses based on different types of bariatric surgery, method of biopsy, and type of histopathologic grading systems, study designs including prospective vs retrospective studies, short term (<1 y) vs long-term follow-up evaluation (>1 y), and baseline NAS. A sensitivity analysis was conducted by identifying potential outliers that could contribute to heterogeneity.
Risk of Bias Assessment and Certainty of Evidence
Risk of bias for individual studies was assessed using the Methodological Index for Non-Randomized Studies (MINORS) tool. 29 Quality of evidence for estimates derived from meta-analyses were assessed by Grading of Recommendations, Assessment, Development and Evaluation (GRADE).
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Results
Study Characteristics
From 1695 potentially relevant citations received from electronic databases and searches from reference lists, 32 studies met the inclusion criteria (15 retrospective and 17 prospective cohort studies). 13, [15] [16] [17] [18] [19] [20] [21] There were no randomized controlled trials identified. All studies were single-arm studies examining the effect of bariatric surgery on NAFLD before and after surgery with no comparators. Figure 1 shows a Preferred Reporting Items for Systematic Reviews and MetaAnalyses flow diagram of the study selection process, and study characteristics are reported in detail in 17, 18 Therefore, to allow sufficient time for liver function to improve after surgery, we chose 1 year as the follow-up time for our analyses.
Biopsy method and its subsequent histopathologic grading system varied between studies. Histopathologic grading systems used in the studies were Brunt, Dixon, Lieber, Brazilian Pathology Society, and the NASH Clinical Research Network grading system (Kleiner) ( Table 2) . However, there were many studies that did not clarify the type of grading system or had customized their own method of categorizing the liver biopsy results. In addition, studies used a mix of needle and wedge methods for collecting liver biopsy specimens. The initial number of biopsy specimens for each study and relevant histologic features are reported in Supplementary Table 2. Most studies did not report individual patient data before and after bariatric surgery and instead chose to provide the number of patients with a specific numeric score for each histologic feature before and after surgery. Moreover, all included studies did not explicitly report the number of patients with NAFLD or NASH separately before and after surgery. Bariatric surgeries conducted in the included studies were laparoscopic Roux-en-Y gastric bypass (10 studies), open Roux-en-Y gastric bypass (open RYGB; 14 studies), laparoscopic adjustable gastric banding (9 studies), laparoscopic sleeve gastrectomy (4 studies), sleeve gastrectomy (4 studies), gastroplasty (3 studies), bilio-intestinal bypass (3 studies), biliopancreatic diversion (BPD; 1 study), jejunoileal bypass (JIB; 1 study), and gastric balloon (1 study). From the 32 studies included, 25 studies reported steatosis (n ¼ 1329), 21 reported inflammation (n ¼ 657), 15 reported ballooning degeneration (n ¼ 320), and 22 reported fibrosis (n ¼ 619) at baseline. A metaanalysis of proportions showed a complete resolution of steatosis in 66% of patients (95% CI, 56%-75%), inflammation in 50% of patients (95% CI, 35%-64%), ballooning degeneration in 76% of patients (95% CI, 64%-86%), and fibrosis in 40% of patients (95% CI, 29%-51%) (Figure 2 ). Similar to individual biopsy results, bariatric surgery resulted in a significant decrease in NAS compared with baseline (mean difference, 2.39; 95% CI, 1.58-3.20; P < .001; 11 studies) (Figure 3 ). Heterogeneity was high across all outcomes, ranging from I 2 of 77.15% to 99%. Changes in liver volume were reported in only 2 studies. Both studies measured liver volume by magnetic resonance imaging and showed significant reductions in liver volume 6 months after bariatric surgery.
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Histologic Worsening of Nonalcoholic Fatty Liver Disease
Histologic worsening in regard to NAFLD-relevant outcomes was reported in a limited number of studies. Nineteen studies reported histologic worsening after the surgery and reported worsening or new development of NAFLD characteristics such as fibrosis (12 studies), steatosis (2 studies), and inflammation (4 studies) after surgery. The development or worsening of NAFLD occurred in 12% of patients (95% CI, 5%-20%) (Supplementary Figure 1) . Other adverse effects, including postoperative complications, are reported in Supplementary Table 3 .
Subgroup Analyses
The majority of bariatric procedures conducted across all meta-analyzed outcomes were RYGB or laparoscopic Roux-en-Y gastric bypass. Other procedures such as laparoscopic adjustable gastric banding, laparoscopic sleeve gastrectomy, sleeve gastrectomy, gastroplasty, bilio-intestinal bypass, BPD, and JIB each were reported in fewer than 5 studies across all outcomes. When more than 1 bariatric procedure was conducted, studies often did not report separate outcomes. Therefore, we only conducted the subgroup analysis for studies that solely conducted RYGB. Complete resolution was higher in proportion for RYGB across all histologic features compared with combined analyses (steatosis, 80%; range, 66%-91%; inflammation, 57%; range, 29%-83%; ballooning, 80%; range, 65%-91%; and fibrosis, Figure 2) . Moreover, the range of heterogeneity decreased to I 2 of 58.80% to 94.85%. In addition, liver side effects decreased to 8% (range, 2%-15%) for RYGB (Supplementary Figure 3) . Subgroup analyses were conducted based on the histopathologic grading systems (Brunt, Dixon, and NASH Clinical Research Network), methods of biopsy (needle vs wedge), durations of follow-up evaluation (short vs long term), study designs (prospective studies that performed biopsies per protocol vs retrospective studies that used opportunity biopsies), and NAS score before surgery (low NAS, score of 0-4; high NAS, score >4). According to the subgroup analyses, steatosis resolved in as high as 89% and in as low as 51% of patients, lobular inflammation resolved in as high as 70% and in as low as 40% of patients, ballooning degeneration resolved in as high as 93% and in as low as 66% of patients, and fibrosis resolved in as high as 51% and in as low as 27% of patients. Our analyses did not show any substantial difference compared with the original pooled effect estimates. A comprehensive table of subgroup analyses and results are available in Table 3 .
Upon visual examination of the forest plots, the substantial heterogeneity present across all outcomes was owing to more than 1 study. Even after removing outlier studies that had comparably lower or higher values than other studies, heterogeneity did not decrease to less than 50% in any of the meta-analyzed outcomes. Therefore, we did not conduct a sensitivity analysis by removing specific data points because it likely would have lead to biased results.
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Quality of Evidence
The mean MINORS score of included studies was 12.40 AE 1.08, which indicates a fair quality of evidence for nonrandomized studies. 29 There was a substantial level of agreement among quality assessment scores using the MINORS criteria (intraclass correlation coefficient, 0.98; 95% CI, 0.98-0.99). A comprehensive list of MINORS for included studies are available in Supplementary Table 4 . In brief, all 32 studies were observational and had a clearly stated objective. Most of the studies included consecutive patients (29 of 32 studies), had an established protocol before the study (20 of 32 studies), used unbiased assessment of the study end point such as blind evaluation of outcomes (29 of 32 studies), and had less than 5% to 10% of loss to follow-up evaluation (29 of 32 studies). The mean follow-up period was longer than 12 months in 29 of 32 of studies. However, studies lacked a prospective calculation of study size (2 of 32 studies). The GRADE qualityof-evidence profile is summarized in Supplementary  Tables 5 and 6 in detail. Because of high heterogeneity present in all outcomes, evidence was rated down for inconsistency. Despite the large magnitude of effect, low risk of bias, and adequate event rate and sample size in Table 2 . most outcomes, the certainty of evidence was not upgraded because of the major concerns with inconsistency. 56 Overall, there was a very low certainty of evidence, suggesting the effect of estimate is uncertain.
Thus, further high-quality research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Symmetry shown in our funnel plot suggests that there is a low possibility of publication bias, which might mean that there is a low number of unpublished negative studies 57 (Supplementary Figure 4) .
Discussion
This comprehensive systematic review investigated the effects of bariatric surgery on biopsy-confirmed NAFLD. Bariatric surgery leads to a complete resolution of steatosis, inflammation, ballooning, and fibrosis in 66% (95% CI, 56%-75%), 50% (95% CI, 35%-64%), 76% (95% CI, 64%-86%), and 40% (95% CI, 29%-51%) of patients, respectively. Hepatic fibrosis has long been known to play an important role in the progression to advanced liver disease, and the effects of bariatric surgery on fibrosis has been unclear. 20 Importantly, this systematic review found that fibrosis completely resolves in 40% of patients. Complementing the individual histologic improvements of NAFLD status, this review also shows a reduction in NAS in patients after bariatric surgery (mean difference, 2.39; 95% CI, 1.58-3.20; P < .001).
Previous studies have variably explored the effect of bariatric surgery on NAFLD. A 2008 meta-analysis of 15 cohort studies by Mummadi et al 58 found an improvement or resolution in steatosis in 91.6% of patients, steatohepatitis in 81.3%, and fibrosis in 65.5% after bariatric surgery. However, resolution and improvement of characteristics were reported together, inflating the true benefit experienced by patients. Although there are still no randomized controlled trials (RCTs) 10 years later, our review of 32 studies provides further evidence that bariatric surgery is effective by focusing on the complete resolution of NAFLD. Furthermore, although Mummadi et al 58 claimed that "the risk of progression of inflammatory changes and fibrosis seems to be minimal," our review found a lower resolution of fibrosis and a 12% chance of worsening NAFLD after bariatric surgery. A prospective cohort study of 381 patients by Mathurin et al 18 found an improvement in steatosis, ballooning, and overall NAS, with a significant reduction in the percentage of NASH patients at 5 years compared with before surgery. However, 5 years after surgery, there was significant worsening of fibrosis in 19.8% of patients for unknown reasons. 18 Our finding that NAFLD worsened or developed after bariatric surgery in 12% of patients pooled from 19 studies confirms the existence of liver side effects such as fibrosis. A Cochrane systematic review by Chavez-Tapia et al 59 found 21 cohort studies in which improvement of steatosis or inflammation were reported after bariatric surgery. Although the review did not include a meta-analysis or examine complete resolution of histologic characteristics, the investigators did identify 4 studies describing some deterioration in the degree of fibrosis. 18, 32, 50, 59 A 2015 meta-analysis by Bower et al 60 associated bariatric surgery with a reduction in the incidence of steatosis, hepatocyte ballooning, lobular inflammation, fibrosis, and reductions in liver enzyme levels. However, the use of liver enzyme levels correlates poorly to histologic findings, and are not reliable in identifying NAFLD and NASH. 61 Nearly 80% of NAFLD patients have normal-range alanine aminotransferase levels, and alanine aminotransferase level typically decreases as fibrosis progresses to cirrhosis. 62, 63 Liver biopsies are the gold standard for diagnosing NASH and assessing NAFLD, and it is for this reason that the present review primarily examines histologic characteristics after bariatric surgery. 61 This study showed a substantial effect of bariatric surgery on the resolution of histopathologic features of NAFLD. Importantly, this study better contextualizes the benefit of bariatric surgery compared with previous studies because it reports complete resolution rather than including improvements, which may or may not be clinically relevant. Accordingly, this study provides a conservative estimate of the proportion of patients with NAFLD who would benefit from bariatric surgery. This study supports the current guidelines, 22, 64 which state that NAFLD as a comorbidity should prompt bariatric surgery in patients with a BMI of 35 to 40 kg/m 2 . Despite the overall favorable histopathologic outcomes, among 19 studies that reported histologic worsening of NAFLD, 12% of patients developed de novo or worsened NAFLD after bariatric surgery. This figure is reported with less precision than the benefits because many studies did not report liver side effects and follow-up biopsies were conducted in a proportion of studies for revision surgeries or unspecified conditions related to the liver. 14, 50, 65 Occasional worsening of NAFLD also may be attributed to the type of bariatric procedures undergone by patients and the extent of malnutrition and malabsorption. 66 JIB and BPD both have been associated with higher liver function morbidity, although the 1 study containing JIB in our review did not report any worsening or adverse events. 66, 67 Despite this, there appears to be a clear net benefit to bariatric surgery for patients with NAFLD. Furthermore, subgroup analyses for RYGB showed a greater reduction of liver side effects and also a higher proportion of complete resolution of NAFLD features. Thus, our analyses continue to support RYGB as the gold standard of bariatric procedures, with the most data to support its safety for the liver.
Future clinical studies should focus on comparative randomized trials that study the effect of bariatric surgery compared with current medical therapy. This is important because although there is a small proportion of patients with progression of disease after bariatric surgery, this proportion likely is smaller than the number of patients who progress on current medical therapy. Therefore, future trials would better elucidate the risks and benefits of surgery compared with standard medical therapy. Longer-term studies also are needed to better understand the benefit of bariatric surgery on liver disease in the context of longer-term outcomes such as liver transplantation, cirrhosis, and liver failure. Finally, if bariatric surgery should be found to be safer and more effective than current medical therapy, consideration may be given to treating patients with aggressive NAFLD and BMIs lower than 35 kg/m 2 with bariatric surgery, which mirrors current recommendations for type II diabetes.
The key strengths of our review included the evaluation of NAS, the most widely used histologic grading and staging system for NAFLD, 61 to offer a broad view of NASH and NAFLD improvement that complements data on individual histologic features. The reporting of complete biopsy-confirmed resolution rather than a combined outcome of improvement and resolution provides a more conservative estimate of patients who absolutely benefit from the procedure. This review also metaanalyzed histologic worsening of NAFLD, focusing on events relevant to NAFLD outcomes that have been described frequently in individual studies. Our review also differs from previous reviews in its rigorous assessment of included studies, both on the individual study level for risk of bias using MINORS, and on the body of evidence level using GRADE. The current consensus for ideal follow-up evaluation rate is 80% or greater of any original cohort in both randomized and prospective studies. 68, 69 The overall follow-up biopsy rate was 85.65% (81.6% for prospective studies only), which indicates that loss to follow-up evaluation was not substantial enough to cause significant attrition bias and impact our results. 68, 69 Our study findings should be interpreted in the light of the following limitations. First, heterogeneity between included studies was high for all outcomes. We attempted to address the heterogeneity by conducting subgroup and sensitivity analyses, but our results failed to explain why heterogeneity is present across pooled effect estimates. A potential cause could be the wide range of follow-up time points across included studies or other comorbidities at an individual patient level. Our study also dichotomized the histopathologic grading system of patients based on individual histologic components; as such, we were unable to determine whether a specific patient suffered from only 1 or multiple histologic features owing to the lack of individual patient data reported by included studies. In addition, the lack of individual patient data precludes us from conducting an individual patient meta-analysis to reliably assess all outcomes and address confounders (eg, difference in follow-up time, type of bariatric surgery, biopsy method, degree of obesity) or conduct a subject-level metaregression to evaluate the percentage of BMI loss correlating with histologic improvement of NAFLD. Finally, all studies were observational with no comparators, which ultimately led to a very low certainty of evidence in all outcomes according to GRADE. There are no RCTs available for this research question to date because blinded RCTs face ethical issues related to equipoise and sham surgery. 70 Open RCTs still would face challenges related to the loss to follow-up evaluation of patients from competing treatments related to cardiovascular risks and liver comorbidities. 59 
Conclusions
The current body of evidence shows bariatric surgery to be beneficial for NAFLD and NASH. Our review shows that bariatric surgery leads to complete resolution in histologic features of NAFLD as well as a significant reduction of NAS in a substantial proportion of patients. Furthermore, the role of RYGB was cemented further as the gold standard procedure for the treatment of NAFLD. However, with the discovery of potential histologic worsening of NAFLD and adverse events as well as the certainty of evidence being very low, further high-quality studies, preferably RCTs, are warranted to recommend bariatric surgery as a therapy for NAFLD remission.
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